{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"18","value":"9"}]}],"title":"Myeloid Chimerism"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4","upperLimit":"22","value":"7"}]}],"title":"Donor T-cell Chimerism"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Median time in months to achieve full myeloid and full donor T-cell Chimerism. Myeloid (CD34+) and T-cell (CD3+) chimerisms were determined by PCR analysis of short tandem repeats (STR). Full donor chimerism is defined as \\>95% donor- derived cells in the peripheral blood in a specific lineage.","dispersionType":"Full Range","groups":[{"description":"Subjects received a nonmyeloablative preparative regimen of alemtuzumab 30mg iv three times a week for two weeks followed by fludarabine 25mg/m\\^2/day for five days followed by a PBPC graft targeted to deliver ≥ 5x10\\^6 CD34+ cells/kg. Cyclosporine A (CSA) for GVHD prophylaxis will be used initially with target CSA levels in the therapeutic range (200 -400 ng/ml).","id":"OG000","title":"Stem Cell Transplant Therapy With Campath-1H"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 22 months","title":"Median Time in Months to Achieve Full Myeloid and Full Donor T-cell Chimerism","type":"SECONDARY","unitOfMeasure":"months"}